Work Here?
Industries
Venture Capital
Social Impact
Financial Services
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$11.5B
Headquarters
Boston, Massachusetts
Founded
1984
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$11488.9M
Above
Industry Average
Funded Over
0 Rounds
Professional Development Budget
Conference Attendance Budget
Bain Capital has acquired Tanabe Mitsubishi Pharmaceutical from Mitsubishi Chemical Group for $3.3 billion. The deal, expected to close in Q3 2025, will make Tanabe an independent company. Bain Capital aims to introduce innovative drugs to Japan and leverage Tanabe's platform for commercial collaborations. This acquisition aligns with Japan's relaxed drug approval regulations, offering growth opportunities in the Japanese life sciences industry.
Bain Capital Private Equity has signed a definitive agreement to acquire Italmatch Chemicals from Ardian. Italmatch, founded in 1997, is a global specialty chemical additive manufacturer with 2017 sales of approximately €400 million. The company operates 17 manufacturing sites globally. The transaction, subject to regulatory approval, marks a new growth phase for Italmatch, leveraging Bain Capital's expertise in the chemical sector.
Bain Capital finalises €4bn acquisition of Apleona from PAI Partners Bain Capital completed the acquisition of German facility management company Apleona from PAI Partners in a deal valued at approximately €4bn ($4.2bn). The transaction marks one of the most significant private equity deals in the European facility management sector in recent years. Apleona, formerly part […]
SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare service
Bain Capital, a Boston, MA-based global private investment firm, announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation, an Osaka, Japan-based company developing drugs, in a carve-out transaction from Mitsubishi Chemical Group Corporation.The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (3.3 billion USD). The deal is expected to close in the third quarter of 2025 and is subject to customary closing conditions, regulatory clearance and shareholder approvals.As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities, enhanced RD productivity, commercialization and strategic acquisitions.Founded in 1678, Tanabe Pharma focuses on several priority therapeutic areas, including immunology inflammation, vaccines, central nervous system (CNS), diabetes and metabolic disease. It employs over 5,000 people globally.Founded in 1984, Bain Capital is a private investment firms committed to creating impact for its investors, teams, businesses, and the communities. Its global platform invests across five focus areas: Private Equity, Growth Venture, Capital Solutions, Credit Capital Markets, and Real Assets. FinSMEs 10/02/2025
Find jobs on Simplify and start your career today
Industries
Venture Capital
Social Impact
Financial Services
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$11.5B
Headquarters
Boston, Massachusetts
Founded
1984
Find jobs on Simplify and start your career today